These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 10597211)
1. Prediction models for the histology of residual masses after chemotherapy for metastatic testicular cancer. ReHiT Study Group. Steyerberg EW; Keizer HJ; Habbema JD Int J Cancer; 1999 Dec; 83(6):856-9. PubMed ID: 10597211 [TBL] [Abstract][Full Text] [Related]
2. Residual masses after chemotherapy for metastatic testicular cancer: the clinical implications of the association between retroperitoneal and pulmonary histology. Re-analysis of Histology in Testicular Cancer (ReHiT) Study Group. Steyerberg EW; Donohue JP; Gerl A; Toner GC; Schraffordt Koops H; Fosså SD; Keizer HJ J Urol; 1997 Aug; 158(2):474-8. PubMed ID: 9224327 [TBL] [Abstract][Full Text] [Related]
4. Teratoma in primary testis tumor reduces complete response rates in the retroperitoneum after primary chemotherapy. The case for primary retroperitoneal lymph node dissection of stage IIb germ cell tumors with teratomatous elements. Rabbani F; Gleave ME; Coppin CM; Murray N; Sullivan LD Cancer; 1996 Aug; 78(3):480-6. PubMed ID: 8697394 [TBL] [Abstract][Full Text] [Related]
5. Sequential resection of residual abdominal and thoracic masses after chemotherapy for metastatic non-seminomatous germ cell tumours. Gerl A; Clemm C; Schmeller N; Dienemann H; Weiss M; Kriegmair M; Löhrs U; Wilmanns W Br J Cancer; 1994 Nov; 70(5):960-5. PubMed ID: 7524606 [TBL] [Abstract][Full Text] [Related]
6. Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours. Hartmann JT; Candelaria M; Kuczyk MA; Schmoll HJ; Bokemeyer C Eur J Cancer; 1997 May; 33(6):843-7. PubMed ID: 9291803 [TBL] [Abstract][Full Text] [Related]
7. Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors. Aprikian AG; Herr HW; Bajorin DF; Bosl GJ Cancer; 1994 Aug; 74(4):1329-34. PubMed ID: 8055456 [TBL] [Abstract][Full Text] [Related]
8. Resection of residual retroperitoneal masses in testicular cancer: evaluation and improvement of selection criteria. The ReHiT study group. Re-analysis of histology in testicular cancer. Steyerberg EW; Keizer HJ; Fosså SD; Sleijfer DT; Bajorin DF; Donohue JP; Habbema JD Br J Cancer; 1996 Nov; 74(9):1492-8. PubMed ID: 8912551 [TBL] [Abstract][Full Text] [Related]
9. Postchemotherapy resections of residual masses from metastatic non-seminomatous testicular germ cell tumors. Hartmann JT; Schmoll HJ; Kuczyk MA; Candelaria M; Bokemeyer C Ann Oncol; 1997 Jun; 8(6):531-8. PubMed ID: 9261521 [TBL] [Abstract][Full Text] [Related]
10. Size and status of metastases after inductive chemotherapy of germ-cell tumors. Indication for salvage operation. Jaeger N; Weissbach L; Bussar-Maatz R World J Urol; 1994; 12(4):196-9. PubMed ID: 7820141 [TBL] [Abstract][Full Text] [Related]
11. Predictors of residual mass histology following chemotherapy for metastatic non-seminomatous testicular cancer: a quantitative overview of 996 resections. Steyerberg EW; Keizer HJ; Stoter G; Habbema JD Eur J Cancer; 1994; 30A(9):1231-9. PubMed ID: 7999405 [TBL] [Abstract][Full Text] [Related]
12. Results of postchemotherapy adjunctive retroperitoneal lymph node dissection in non-seminomatous germ cell cancer patients. Goepel M; Recker F; Otto T; Krege S; Rübben H Urol Int; 1996; 57(4):209-12. PubMed ID: 8961487 [TBL] [Abstract][Full Text] [Related]
13. Clinical outcome of retroperitoneal lymph node dissection after induction chemotherapy for metastatic non-seminomatous germ cell tumors. Muramaki M; Hara I; Miyake H; Yamada Y; Okada H; Kamidono S Int J Urol; 2004 Sep; 11(9):763-7. PubMed ID: 15379941 [TBL] [Abstract][Full Text] [Related]
14. Validation of a prediction model and its predictors for the histology of residual masses in nonseminomatous testicular cancer. Vergouwe Y; Steyerberg EW; Foster RS; Habbema JD; Donohue JP J Urol; 2001 Jan; 165(1):84-8; discussion 88. PubMed ID: 11125370 [TBL] [Abstract][Full Text] [Related]
15. Testicular tumors: residual retroperitoneal mass surgery after chemotherapy;Is it possible to predict their histology? Medina-Polo J; Martínez-Silva V; Domínguez-Esteban M; de la Rosa-Kehrmann F; Villacampa-Aubá F; Castellano-Gauna D; Díaz-González R Arch Esp Urol; 2011 Sep; 64(7):611-9. PubMed ID: 21965259 [TBL] [Abstract][Full Text] [Related]
16. Post-chemotherapy residual mass in non-seminomatous testicular cancer. The role of retroperitoneal lymph node dissection. El Sayed S; Grando JP; Almeida SH; Mortati Neto N; Moreira HA Int Braz J Urol; 2004; 30(5):384-8. PubMed ID: 15610570 [TBL] [Abstract][Full Text] [Related]
17. Chemotherapy of testicular cancer: 10-year experience. Ondrus D; Hornák M; Matoska J; Kausitz J; Belan V; Cársky S Neoplasma; 1993; 40(4):247-53. PubMed ID: 7505886 [TBL] [Abstract][Full Text] [Related]
18. Resection of residual masses alone: an alternative in surgical therapy of metastatic testicular germ cell tumors after chemotherapy. Ozen H; Ekici S; Sozen S; Ergen A; Tekgül S; Kendi S Urology; 2001 Feb; 57(2):323-7. PubMed ID: 11182346 [TBL] [Abstract][Full Text] [Related]
19. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. Steyerberg EW; Keizer HJ; Fosså SD; Sleijfer DT; Toner GC; Schraffordt Koops H; Mulders PF; Messemer JE; Ney K; Donohue JP J Clin Oncol; 1995 May; 13(5):1177-87. PubMed ID: 7537801 [TBL] [Abstract][Full Text] [Related]
20. Histology of tumor residuals following chemotherapy in patients with advanced nonseminomatous testicular cancer. Fosså SD; Aass N; Ous S; Høie J; Stenwig AE; Lien HH; Paus E; Kaalhus O J Urol; 1989 Nov; 142(5):1239-42. PubMed ID: 2478726 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]